secwatch.observer — SEC 8-K summary
======================================

Issuer:     INNOVATE Corp. (VATE)
CIK:        0001006837
Form:       8-K
Filed at:   2024-05-07T23:59:59+00:00
Accession:  0001006837-24-000078
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

INNOVATE Q1 revenue $315M (-0.8%); net loss $17.7M, adj EBITDA $12.8M (+161%)
-----------------------------------------------------------------------------

- Revenue $315.2M (down 0.8% YoY); net loss attributable to common $17.7M vs $10.2M loss in Q1 2023.
- Total adjusted EBITDA $12.8M (up 161% YoY), driven by margin expansion at DBMG and cost cuts at R2.
- Infrastructure revenue $307.9M, net income $4.4M; backlog $0.9B reported, $1.2B adjusted.
- Life Sciences: R2 record North America system sales (400+ units); MediBeacon in ongoing FDA discussions.
- Closed rights offering Apr 24: issued 5.3M common at $0.70 ($3.7M) and 31.3K preferred to Lancer ($31.3M).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1006837/000100683724000078/0001006837-24-000078-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1006837/000100683724000078/hchc-20240507.htm
  HTML page:      https://secwatch.observer/filing/0001006837-24-000078

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer